Latest news

• AbbVie reports more solid data for would-be psoriasis blockbuster

  AbbVie’s drug is in hot pursuit of the only approved IL-23 inhibitor on the market - J&J’s Tremfya (guselkumab) - and some analysts including Leerink’s Geoffrey Porges have

• Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

  as well as Johnson &Johnson’s IL-23 blocker Tremfya (guselkumab) which was approved in Europe towards the end of last year.

• Janssen’s Tremfya cleared for European use

  Janssen’ s Tremfya cleared for European use. EC approves the medicine to treat adults with plaque psoriasis. ... Meanwhile beyond the plaque psoriasis indication, Janssen is further studying Tremfya, in a phase III psoriatic arthritis development

• AbbVie risankizumab trials set up psoriasis filing - and a market battle

  Since its debut in 2015 Cosentyx has been joined by IL-17 inhibitors from Eli Lilly and Valeant, while Johnson &Johnson has IL-23 blocker Tremfya (guselkumab) approved in the US

• J&J files would-be prostate cancer blockbuster in US

  That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)